Structure Therapeutics Financial Statements
NASDAQ: GPCRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
25.54-0.13 (-0.51%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Structure Therapeutics revenue and earnings
Structure Therapeutics reported a net loss of $141.2 million, compared with a loss of $122.5 million a year earlier. Diluted earnings per share came in at -$0.80.
Summary generated from market data by MetaCap's automated system. Methodology
Structure Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 |
|---|---|---|---|---|
| Operating Expenses | 176.56M | 158.23M | 102.78M | 52.56M |
| Research & Development | 225.25M | 108.81M | 70.10M | 36.19M |
| Operating Income | -176.56M | -158.23M | -102.78M | -52.56M |
| Pretax Income | -140.69M | -122.22M | -89.38M | -51.30M |
| Income Tax | 515.00K | 310.00K | 236.00K | 17.00K |
| Net Income | -141.20M | -122.53M | -89.62M | -51.32M |
| Net Income growth (YoY) | — | — | — | — |
| EPS (Basic) | -0.80 | -0.78 | -0.81 | -5.51 |
| EPS (Diluted) | -0.80 | -0.78 | -0.81 | -5.51 |
| Shares Outstanding (Basic) | 177.60M | 157.92M | 110.20M | 9.58M |
| Shares Outstanding (Diluted) | 177.60M | 157.92M | 110.20M | 9.58M |
| EBITDA | -175.23M | -157.24M | -102.48M | -52.28M |
This table shows 4 annual periods of Structure Therapeutics's income statement, from FY 2025 back to FY 2022, across 11 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow GPCR's reporting calendar. What is a income statement?